| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06176768 | A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis | PHASE2 | COMPLETED | 33 | — | — | Dec 6, 2023 | May 6, 2025 | Oct 15, 2025 | 12 | United States |
* The PASI is an investigator-administered, multi-item scale used to measure the severity of psoriasis based on lesion severity and the percent of body surface area (BSA) affected. * Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomical regions: head, trunk, upper limbs, lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). * The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region, and then multiplied by a constant corresponding to the region's percent BSA (0.1, 0.3, 0.2, and 0.4 for the above 4 regions, respectively). The resultant score for each anatomic region is then summed to yield the final PASI score. It ranges from 0 to 72, with higher scores reflecting greater disease severity. * The nonresponder imputation (NRI) method was used to handle missing data.
| Arm | Type | Description |
|---|---|---|
| LY3972406 | EXPERIMENTAL | Participants received an oral dose of LY3972406 for 12 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants received an oral dose of placebo for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3972406 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline * Have venous access sufficient to allow for blood sampling * Are able to swallow oral medication Exclusion Criteria: * Have any other skin conditions, excluding plaque psoriasis * Have ...